AXNX — Axonics Income Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
- $3.63bn
- $3.28bn
- $366.38m
Annual income statement for Axonics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13.8 | 112 | 180 | 274 | 366 |
| Cost of Revenue | |||||
| Gross Profit | 7.33 | 67.1 | 116 | 198 | 275 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 94.4 | 165 | 252 | 339 | 392 |
| Operating Profit | -80.6 | -53.8 | -71.8 | -64.9 | -26.1 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -79.9 | -54.9 | -79.3 | -62.3 | -8.74 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -79.9 | -54.9 | -80.1 | -59.7 | -6.09 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -79.9 | -54.9 | -80.1 | -59.7 | -6.09 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -79.9 | -54.9 | -80.1 | -59.7 | -6.09 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.8 | -1.48 | -1.79 | -0.964 | 0.269 |